The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

Allergan Generics

Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business

Frutarom

Advised IFF, a leading innovator of specialty ingredients, on its acquisition of Frutarom, creating a global leader in Taste, Scent and Nutrition

Digicel Group

Advised PGIM, Contrarian Capital Management, and GoldenTree Asset Management on the restructuring of Digicel Group, a communications and entertainment provider with operations in 25 Caribbean and Central American markets

Verizon Communications Inc.

(various assets)
Provided independent valuation services in connection with the acquisition by América Móvil and Telmex of a 100% stake in Verizon Dominicana, an approximate 52% stake in Telecomunicaciones de Puerto Rico and an approximate 28.5% stake in Compania Anónima Nacional Teléfonos de Venezuela

Cigarrera La Moderna

, subsidiary of Empresas La Moderna Advised Empresas La Moderna on the sale of its subsidiary Cigarrera La Moderna, Mexico’s largest cigarette producer, for a combination of cash and redeemable notes

Tate & Lyle PLC’s Primary Products business in North America and Latin America (50% stake)

Advising Tate & Lyle PLC, a leading UK-based global provider of food and beverage ingredients and solutions, on its sale of a controlling stake in its Primary Products business in North America and Latin America

Derco Holdings

Advising and acting as sponsor to Inchcape plc, the leading independent global automotive distributor, on its proposed Class 1 acquisition of Derco, the largest independent automotive distributor by volume in Latin America

Pegaso Telecomunicaciones

Advised Pegaso, Mexico’s No. 2 wireless provider, on its financial restructuring and subsequent sale of 65% stake to Telefonica

Pegaso Telecommunications
Advised Pegaso, Mexico’s No. 2 wireless provider, on its financial restructuring and subsequent sale of 65% stake to Telefonica for $1.36 billion

Procaps Group

Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"

Renewable assets in Chile involving hybrid solar power generation and storage

Advised ContourGlobal (KKR) in the acquisition of 3 independent solar (Quillagua I & II, and Victor Jara) and BESS projects from Grenergy

Repsol Renovables

Advised Energy Infrastructure Partners, Swiss investment fund specialized in energy infrastructure, in consortium with Credit Agricole Assurance, French insurance subsidiary of Credit Agricole, in the acquisition of a 25% stake in Repsol Renovables, the international renewable energy platform of Repsol

NII Holdings’ operations in Brazil (“Nextel Brazil”)

Advised NII Holdings, a provider of mobile communications services in Brazil, on the sale of its 70% interest in its operations in Brazil (“Nextel Brazil”) to América Móvil

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)

US rights to 37 approved and 5 pipeline generic products

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
Haleon plc’s Nicotine Replacement Therapy Business (ex-US)

Advising Haleon plc on the sale of its global nicotine replacement therapy business (ex-US) to Dr. Reddy’s Laboratories

US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.

Seguros Comercial América

, S.A. de C.V. (stake owned by Savia S.A. de C.V.)
Advised Savia on the sale of a minority stake in Seguros Comercial América, the largest Mexican insurance company, to ING Groep.

J. Malucelli Participacao em Seguros E Resseguros S.A

Advised Travelers, the largest listed property and casualty insurance company in the U.S., on the acquisition of a ~43% stake in J. Malucelli Participacao em Seguros E Resseguros, the leading surety insurance company in Brazil, through the issue of new common shares (with an option to increase to 49.9% within 18 months)

US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories

Desktop Metal, Inc.

Advising Nano Dimension, a developer of 3D printing and Additive Manufacturing technologies, predominantly for A&D applications, on its acquisition of Desktop Metal, a vertically integrated 3D printers, materials and software company and pioneer of several 3D printing technologies

Subsidiaries and affiliates of Empresas Indumotora S.A.

Advised Inchcape PLC, a global leader in automotive retail and distribution, on the acquisition of a multi-country scale distribution business in Chile, Peru, Colombia, and Argentina for $290m (approximately £234m)

Republic Companies Group, Inc.

Advised Republic Companies Group, Inc., a regional provider of personal and commercial property and casualty insurance products

Grupo Rudelman

Advised Inchcape PLC, a global leader in automotive and distribution, on the acquisition of Grupo Rudelman, a Suzuki-focused distribution business in Costa Rica and Panama

Taro Pharmaceutical Industries

Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company